{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:27:07Z","timestamp":1793453227775,"version":"4.5.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Etranacogene dezaparvovec (CSL222, formerly AMT-061) is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing the highly active factor IX (FIX) Padua variant controlled by a liver-specific promoter. This phase 2b, open-label, single-dose, single-arm, multicenter trial evaluated the efficacy and safety of etranacogene dezaparvovec. Three adult participants with severe or moderately severe hemophilia B (FIX \u22642%) and AAV5-neutralizing antibodies received a single IV dose (2 \u00d7 1013 genome copies per kg) of etranacogene dezaparvovec. The primary end point of FIX activity \u22655 IU\/dL at 6 weeks was met (mean, 30.6 IU\/dL). Secondary end points included bleed frequency, FIX concentrate use, and adverse events. Here, we report the end-of-study 5-year outcomes. After administration, mean (range) FIX activity increased to 40.8 IU\/dL (31.3-50.2) at year 1 and was maintained at 45.7 IU\/dL (39.0-51.2) at year 5. Mean annualized bleeding rate (all bleeds) was 0.14 for the cumulative follow-up period years 0 to 5. Two participants had 5 bleed-free years after treatment. Per protocol, 1 participant received episodic FIX replacement therapy after treatment for elective surgeries, 2 bleeding episodes, and 2 single self-administered infusions for unreported reasons. All participants discontinued and remained free of FIX prophylaxis. During the 5-year study period, there were no clinically significant elevations in liver enzymes, requirement for steroids, FIX inhibitor development, thrombotic complications, or late-emergent safety events in any participant. Five years after administration, etranacogene dezaparvovec was effective in adults with hemophilia B with a favorable safety profile. Participants are eligible to participate in an extension study (ClinicalTrials.gov identifier: NCT05962398) for 10-year additional follow-up. This trial was registered at www.clinicaltrials.gov as #NCT03489291.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015291","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T13:18:46Z","timestamp":1743945526000},"page":"3543-3552","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-6322","authenticated-orcid":false,"given":"Annette","family":"von Drygalski","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Gomez","sequence":"additional","affiliation":[{"name":"2Center for Inherited Blood Disorders, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giermasz","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, Hemophilia Treatment Center, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"4Center for Bleeding Disorders, Department of Oncology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-4304","authenticated-orcid":false,"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Blood Research Center, Department of Medicine, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-0257","authenticated-orcid":false,"given":"Susan U.","family":"Lattimore","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, The Hemostasis and Thrombosis Center, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Erasmus Medical Centre, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Miesbach","sequence":"additional","affiliation":[{"name":"8Department of Hemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Recht","sequence":"additional","affiliation":[{"name":"9National Bleeding Disorders Foundation, New York, NY"},{"name":"10Division of Pediatric Hematology-Oncology, Center for Bleeding and Clotting Disorders, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Monahan","sequence":"additional","affiliation":[{"name":"11Hematology Clinical Development, CSL Behring, King of Prussia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-3946","authenticated-orcid":false,"given":"Sandra","family":"Le Quellec","sequence":"additional","affiliation":[{"name":"11Hematology Clinical Development, CSL Behring, King of Prussia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-2089","authenticated-orcid":false,"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[{"name":"12Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"suppl 6","key":"2025072209163282400_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"2025072209163282400_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"10274","key":"2025072209163282400_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2025072209163282400_bib4","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1111\/hae.14098","article-title":"Optimal trough levels in haemophilia B: raising expectations","volume":"26","author":"Walsh","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"2025072209163282400_bib5","first-page":"70","article-title":"Gene transfer in hemophilia B: a big step forward. Bleeding Throm Vasc","volume":"2","author":"Castaman","year":"2023","journal-title":"Biology"},{"issue":"9","key":"2025072209163282400_bib6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2025072209163282400_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025072209163282400_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2025072209163282400_bib9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"2025072209163282400_bib10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2025072209163282400_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2025072209163282400_bib12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17474086.2023.2276206","article-title":"Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B","volume":"16","author":"Castaman","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2025072209163282400_bib13","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1097\/HS9.0000000000000540","article-title":"Hemophilia gene therapy: approaching the first licensed product","volume":"5","author":"Batty","year":"2021","journal-title":"Hemasphere"},{"issue":"1","key":"2025072209163282400_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13023-024-03181-2","article-title":"A 360-degree perspective on adeno-associated virus (AAV)-based gene therapy for haemophilia: insights from the physician, the nurse and the patient","volume":"19","author":"Miesbach","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"2025072209163282400_bib15","unstructured":"Study of AAV5-hFIX in severe or moderately severe haemophilia B ClinicalTrials.gov identifier: NCT05360706. Updated 21 March 2025. Accessed 24 April 2025. https:\/\/clinicaltrials.gov\/study\/NCT05360706."},{"issue":"suppl 1","key":"2025072209163282400_bib16","first-page":"18","article-title":"First report of a long-term follow-up extension study 6 years after gene therapy with AMT-060 in adults with hemophilia B confirms safety and stable FIX expression and sustained reductions in factor IX use","volume":"30","author":"Miesbach","year":"2024","journal-title":"Haemophilia"},{"issue":"21","key":"2025072209163282400_bib17","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"2025072209163282400_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced factor IX activity following administration of AAV5-R338L \u201cPadua\u201d factor IX versus AAV5 WT human factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"19","key":"2025072209163282400_bib19","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"2025072209163282400_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"2025072209163282400_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol Ther"},{"issue":"1","key":"2025072209163282400_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025072209163282400_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025072209163282400_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"issue":"4","key":"2025072209163282400_bib25","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"2025072209163282400_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025072209163282400_bib27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood-2023-187624","article-title":"Long-term bleeding protection, sustained FIX activity, reduction of FIX consumption and safety of hemophilia B gene therapy: results from the HOPE-B trial 3 years after administration of a single dose of etranacogene dezaparvovec in adult patients with severe or moderately severe hemophilia B","volume":"142","author":"Pipe","year":"2023","journal-title":"Blood"},{"key":"2025072209163282400_bib28","first-page":"26330040211058896","article-title":"Etranacogene dezaparvovec for hemophilia B gene therapy","volume":"2","author":"Thornburg","year":"2021","journal-title":"Ther Adv Rare Dis"},{"issue":"3","key":"2025072209163282400_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.13140","article-title":"Measurement properties of the Haem-A-QoL in haemophilia clinical trials","volume":"23","author":"von Mackensen","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"2025072209163282400_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/hgtb.2015.037","article-title":"Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system","volume":"26","author":"Meliani","year":"2015","journal-title":"Hum Gene Ther Methods"},{"issue":"suppl 4","key":"2025072209163282400_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.14545","article-title":"Gene therapy: practical aspects of implementation","volume":"28","author":"Pipe","year":"2022","journal-title":"Haemophilia"},{"issue":"12","key":"2025072209163282400_bib32","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2025072209163282400_bib33","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025072209163282400_bib34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants","volume":"5","author":"Samelson-Jones","year":"2021","journal-title":"Blood Adv"},{"key":"2025072209163282400_bib35","unstructured":"Long-term follow-up study of male adults with hemophilia B previously treated with etranacogene dezaparvovec (CSL222) (IX-TEND 3003) ClinicalTrials.gov identifier: NCT05962398. Updated 2 April 2025. Accessed 24 April 2025. https:\/\/clinicaltrials.gov\/study\/NCT05962398."},{"key":"2025072209163282400_bib36","unstructured":"HEMGENIX. Prescribing information. CSL Behring. 2022. Accessed 24 April 2025. https:\/\/www.fda.gov\/media\/163467\/download."},{"key":"2025072209163282400_bib37","unstructured":"HEMGENIX. Summary of product characteristics. CSL Behring. 2024. Accessed 24 April 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemgenix-epar-product-information_en.pdf."},{"key":"2025072209163282400_bib38","unstructured":"Hemgenix (etranacogene dezaparvovec). Australian prescription medicine decision summary. Australian Government Department of Health and Aged Care. 2024. Accessed 24 April 2025. https:\/\/www.tga.gov.au\/resources\/auspmd\/hemgenix-etranacogene-dezaparvovec."},{"issue":"suppl 1","key":"2025072209163282400_bib39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2023-186891","article-title":"Stable therapeutic transgenic FIX levels for more than 10 years in subjects with severe hemophilia B who received scAAV2\/8-LP1-hfixco adeno-associated virus gene therapy","volume":"142","author":"Reiss","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025072209163282400_bib40","first-page":"49","article-title":"Four-year results of etranacogene dezaparvovec in haemophilia B patients with pre-existing AAV5 neutralising antibodies: phase 3 HOPE-B trial","volume":"31","author":"Klamroth","year":"2025","journal-title":"Haemophilia"},{"key":"2025072209163282400_bib41","unstructured":"BEQVEZ. Prescribing information. Pfizer. 2024. Accessed 24 April 2025. https:\/\/www.fda.gov\/media\/178140\/download."},{"key":"2025072209163282400_bib42","unstructured":"Durveqtix. Summary of product characteristics. (EMA) EMA. 2024. Accessed 24 April 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/durveqtix-epar-product-information_en.pdf."},{"key":"2025072209163282400_bib43","unstructured":"A study to evaluate the efficacy and safety of factor IX gene therapy with PF-06838435 in adult males with moderately severe to severe hemophilia B (BENEGENE-2) ClinicalTrials.gov identifier: NCT03861273. Updated 17 April 2025. Accessed 24 April 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03861273."},{"issue":"6","key":"2025072209163282400_bib44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/ejh.13055","article-title":"Impact of hemophilia B on quality of life in affected men, women, and caregivers-assessment of patient-reported outcomes in the B-HERO-S study","volume":"100","author":"Buckner","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"2025072209163282400_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","article-title":"Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US+ population surveys","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2025072209163282400_bib46","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/PPA.S239810","article-title":"The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients","volume":"14","author":"Miesbach","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2025072209163282400_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.17225\/jhp00174","article-title":"The patient gene therapy journey: findings from qualitative interviews with trial participants at one UK haemophilia centre","volume":"8","author":"Aradom","year":"2021","journal-title":"J Haemophilia Pract"},{"issue":"3","key":"2025072209163282400_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/hae.14977","article-title":"Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: results from the phase III HOPE-B trial 2 years after gene therapy","volume":"30","author":"Itzler","year":"2024","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3543\/2402645\/blooda_adv-2024-015291-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3543\/2402645\/blooda_adv-2024-015291-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:16:44Z","timestamp":1753190204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/14\/3543\/536584\/Completion-of-phase-2b-trial-of-etranacogene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015291","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,22]]},"published":{"date-parts":[[2025,7,11]]}}}